DrugMapper


Trade Names:	BUMETANIDE BUMEX
Synonyms:	BETINEX BUMETANIDA BUMEX BURINEX LIXIL PF-1593 PF1593 RO 10-6338 RO-10-6338 RO-106338 RO10-6338 S-95008. S95008.
Status:	Approved (1983)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	C03CA02
UNII:	0Y2S3XUQ5H


InChI Key	MAEIEVLCKWDQJH-UHFFFAOYSA-N
Smile	CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
InChI	InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)

Action	Mechanism of Action	Reference
INHIBITOR	Sodium-(potassium)-chloride cotransporter 2 inhibitor

	Primary Target
Kidney-specific Na-K-Cl symporter

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	-	-	-
Enzyme Lyase	-	-	-	3400000	-
Enzyme Transferase	-	-	-	-	30.63
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-23.98-8.26
Ion channel Other ion channel Aquaporin Water-specific aquaporin	-	100000	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC12 family of cation-coupled chloride transporters	-	1540	-	-	58.8-71.7
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	71.95
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	-	-	5500	-
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	526400	-	-	-
Unclassified protein	-	-	-	-

Mesh Heading	Maximum Phase	Mesh ID	Reference
Heart Failure	4	D006333	ClinicalTrials
Child Development Disorders, Pervasive	3	D002659	ClinicalTrials
Autistic Disorder	3	D001321	ClinicalTrials
Alzheimer Disease	2	D000544	ClinicalTrials
Renal Insufficiency, Chronic	2	D051436	ClinicalTrials
Hypokalemic Periodic Paralysis	2	D020514	ClinicalTrials
Down Syndrome	2	D004314	ClinicalTrials
Carcinoma, Hepatocellular	1	D006528	ClinicalTrials
Seizures	1	D012640	ClinicalTrials
Diabetes Mellitus, Type 2	1	D003924	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

Side effects	Relative Frequency (%)	Labels
Metabolism and nutrition disorders Hypochloraemia	14.9
Metabolism and nutrition disorders Hypokalaemia	14.7
Renal and urinary disorders Azotaemia	10.6
Metabolism and nutrition disorders Hyponatraemia	9.2
Investigations Blood creatinine increased	7.4
Endocrine disorders Hyperglycaemia	6.6
Cardiac disorders Dizziness	1.1
Vascular disorders Hypotension	0.8
Renal and urinary disorders Glycosuria	0.7
Nervous system disorders Headache	0.6
Gastrointestinal disorders Nausea	0.6
Hearing impaired	0.5
Skin and subcutaneous tissue disorders Pruritus	0.4
Gastrointestinal disorders Abdominal pain	0.2
Musculoskeletal and connective tissue disorders Arthralgia	0.2
General disorders and administration site conditions Asthenia	0.2
Skin and subcutaneous tissue disorders Dermatitis	0.2
Gastrointestinal disorders Gastrointestinal pain	0.2
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.2
Skin and subcutaneous tissue disorders Rash	0.2
Blood and lymphatic system disorders Thrombocytopenia	0.2
Immune system disorders Urticaria	0.2
Gastrointestinal disorders Vomiting	0.2

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	10.64
Cardiac disorders	10.41
Renal and urinary disorders	9.05
Gastrointestinal disorders	8.29
Metabolism and nutrition disorders	8.15
Vascular disorders	7.54
Nervous system disorders	6.76
Infections and infestations	5.19
Musculoskeletal and connective tissue disorders	5.14
Respiratory, thoracic and mediastinal disorders	4.97
Investigations	4.8
Skin and subcutaneous tissue disorders	4.75
Injury, poisoning and procedural complications	3.69
Psychiatric disorders	3.46
Immune system disorders	2.12

BUMETANIDE


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70